Catalyst Calendar

Wed, Sep 9, 2026

1 updates

7:00 AM

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Data from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, incl...

rezolutebio.com

Wed, Sep 2, 2026

1 updates

RZLT

7:30 AM

Rezolute to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory...

rezolutebio.com

Tue, Jul 21, 2026

1 updates

RZLT

7:30 AM

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory ...

rezolutebio.com